Form 4: Agios Pharmaceuticals Director Reports Routine Stock Acquisition from RSU Vesting

Agios Pharmaceuticals, Inc. Director Catherine Owen reported the vesting and acquisition of 1,977 shares of common stock through the exercise of restricted stock units on June 13, 2025, increasing her direct beneficial ownership to 3,953 shares.

Summary

• Catherine Owen, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported a transaction on June 13, 2025, involving the exercise of restricted stock units.
• The transaction resulted in the acquisition of 1,977 shares of Agios Pharmaceuticals common stock at a price of $0.
• This acquisition was a conversion of 1,977 restricted stock units (RSUs) that were originally granted on June 13, 2023.
• Following this transaction, Catherine Owen directly beneficially owns a total of 3,953 shares of Agios Pharmaceuticals, Inc. common stock.
• The RSUs are scheduled to vest in three equal annual installments, beginning on June 13, 2024, with vested shares delivered within three business days after vesting.

Sentiment

Score: 6

Explanation: The transaction is a routine vesting of restricted stock units, which is an expected compensation event. It indicates the director's continued equity stake in the company, which is generally viewed as a positive alignment of interests, but does not signal new strategic developments or significant financial performance.

Positives

• The transaction represents a routine vesting of restricted stock units, which is a standard component of director compensation.
• The acquisition of common stock increases the director's direct beneficial ownership in the company, further aligning her interests with those of shareholders.

Future Outlook

The document indicates that the restricted stock units granted on June 13, 2023, will continue to vest in three equal annual installments beginning June 13, 2024, with vested shares delivered to the reporting person within three business days after such shares become vested.

Industry Context

This Form 4 filing details a routine insider transaction for a director at a pharmaceutical company. Such transactions are common in the biotech and pharmaceutical industries as part of executive and director compensation packages, often involving equity awards like restricted stock units to align management interests with long-term shareholder value.

Comparison to Industry Standards

• The vesting of restricted stock units is a standard component of executive and director compensation across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• The practice of granting equity awards like RSUs, which vest over time, is a common mechanism to incentivize long-term performance and retention, consistent with compensation practices observed at comparable biopharmaceutical companies.
• Specific comparable companies or projects are not mentioned in this filing, as it focuses solely on an individual's transaction.

Related Party Transactions

• The transaction is an insider transaction (between the company and a director) related to compensation, specifically the vesting of restricted stock units, which is a standard compensation mechanism.

Stakeholder Impact

• Shareholders: The vesting and acquisition of shares by a director can be seen as a positive signal of continued alignment of interests. It also represents a minor increase in outstanding shares due to the conversion of RSUs.

Next Steps

• Future vesting installments of the restricted stock units granted on June 13, 2023, will occur annually.
• Vested shares will be delivered to the reporting person within three business days after they become vested.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Beneficial Ownership, Director Compensation, Catherine Owen